RESUMEN
Clinical studies have reported beneficial effects of a maternal low glycaemic index (GI) diet on pregnancy and neonatal outcomes, but the impact of the diet on the offspring in later life, and the mechanisms underlying these effects, remain unclear. In this study, Albino Wistar rats were fed either a low GI (n=14) or high GI (n=14) diet during pregnancy and lactation and their offspring weaned onto either the low or high GI diet. Low GI dams had better glucose tolerance (AUC[glucose], 1322±55 v. 1523±72 mmol min/l, P<0.05) and a lower proportion of visceral fat (19.0±2.9 v. 21.7±3.8% of total body fat, P<0.05) compared to high GI dams. Female offspring of low GI dams had lower visceral adiposity (0.45±0.03 v. 0.53±0.03% body weight, P<0.05) and higher glucose tolerance (AUC[glucose], 1243±29 v. 1351±39 mmol min/l, P<0.05) at weaning, as well as lower hepatic PI3K-p85 mRNA at 12 weeks of age. No differences in glucose tolerance or hepatic gene expression were observed in male offspring, but the male low GI offspring did have reduced hepatic lipid content at weaning. These findings suggest that consuming a low GI diet during pregnancy and lactation can improve glucose tolerance and reduce visceral adiposity in the female offspring at weaning, and may potentially produce long-term reductions in the hepatic lipogenic capacity of these offspring.
RESUMEN
INTRODUCTION: We sought to determine the patient and provider-related factors associated with readmission after radical cystectomy (RC) for bladder cancer. In this era of healthcare reform, hospital performance measures, such as readmission, are beginning to affect provider reimbursement. Given its high readmission rate, RC could be a target for quality improvement. METHODS: We reviewed bladder cancer patients who underwent RC in California's State Inpatient Database (2005-2009) of the Healthcare Cost and Utilization Project. We examined patient-(e.g., race, discharge disposition) and provider-related factors (e.g., volume) and evaluated their association with 30-day readmission. Multivariable logistic regression was used to examine associations of interest. RESULTS: Overall, 22.8% (n = 833) of the 3649 patients who underwent RC were readmitted within 30 days. Regarding disposition, 34.8%, 50.8%, and 12.2% were discharged home, home with home healthcare, and to a post-acute care facility (PACF), respectively. Within 30 days, 20.3%, 20.9%, and 42.3% were discharged home, home with home healthcare, and to a PACF were readmitted, respectively. African Americans (odds ratio [OR] 1.64, 95% confidence interval [CI] 1.07-2.50), having ≥2 comorbidities (OR 1.42, 95% CI 1.06-1.91), receiving a neobladder (OR 1.45, 95% CI 1.09-1.93), and discharged to a PACF (OR 3.79, 95% CI 2.88-4.98) were independent factors associated with readmission. Hospital stays ≥15 days were associated with less readmission (OR 0.43, 95% CI 0.27-0.67, p = 0.0002). Procedure volume was not associated with complication, in-hospital mortality, or readmission. CONCLUSIONS: About one-fifth of patients undergoing RC are readmitted. Patients who are discharged to a PACF, African American, and who have more extensive comorbidities tend to experience more readmissions. Increased efforts with care coordination among these patients may help reduce readmissions.
RESUMEN
No abstract available.
RESUMEN
A pre-use check to ensure the correct functioning of anaesthetic equipment is essential to patient safety. The anaesthetist has a primary responsibility to understand the function of the anaesthetic equipment and to check it before use. Anaesthetists must not use equipment unless they have been trained to use it and are competent to do so. A self-inflating bag must be immediately available in any location where anaesthesia may be given. A two-bag test should be performed after the breathing system, vaporisers and ventilator have been checked individually. A record should be kept with the anaesthetic machine that these checks have been done. The 'first user' check after servicing is especially important and must be recorded.
Asunto(s)
Anestesiología/instrumentación , Lista de Verificación , Manejo de la Vía Aérea/instrumentación , Anestesia Intravenosa , Anestésicos por Inhalación , Suministros de Energía Eléctrica , Falla de Equipo , Seguridad de Equipos , Humanos , Irlanda , Auditoría Administrativa , Monitoreo Intraoperatorio/instrumentación , Resucitación/instrumentación , Reino Unido , Ventiladores Mecánicos/normasAsunto(s)
Anomalías Múltiples/genética , Enanismo/congénito , Enanismo/genética , Insuficiencia Respiratoria/congénito , Insuficiencia Respiratoria/genética , Sobrevivientes , Anomalías Múltiples/diagnóstico por imagen , Anomalías Múltiples/etiología , Adolescente , Adulto , Niño , Consanguinidad , Enanismo/complicaciones , Enanismo/diagnóstico por imagen , Genes Letales , Humanos , Masculino , Fenotipo , Radiografía , Insuficiencia Respiratoria/complicacionesRESUMEN
Central infusion of angiotensin IV or its more stable analogues facilitates memory retention and retrieval in normal animals and reverses amnesia induced by scopolamine or by bilateral perforant pathway lesions. These peptides bind with high affinity and specificity to a novel binding site designated the angiotensin AT(4) receptor. Until now, the AT(4) receptor has eluded molecular characterization. Here we identify the AT(4) receptor, by protein purification and peptide sequencing, to be insulin-regulated aminopeptidase (IRAP). HEK 293T cells transfected with IRAP exhibit typical AT(4) receptor binding characteristics; the AT(4) receptor ligands, angiotensin IV and LVV-hemorphin 7, compete for the binding of [(125)I]Nle(1)-angiotensin IV with IC(50) values of 32 and 140 nm, respectively. The distribution of IRAP and its mRNA in the brain, determined by immunohistochemistry and hybridization histochemistry, parallels that of the AT(4) receptor determined by radioligand binding. We also show that AT(4) receptor ligands dose-dependently inhibit the catalytic activity of IRAP. We have therefore demonstrated that the AT(4) receptor is IRAP and propose that AT(4) receptor ligands may exert their effects by inhibiting the catalytic activity of IRAP thereby extending the half-life of its neuropeptide substrates.
Asunto(s)
Aminopeptidasas/metabolismo , Angiotensina II/análogos & derivados , Angiotensina II/metabolismo , Receptores de Angiotensina/metabolismo , Aminopeptidasas/antagonistas & inhibidores , Aminopeptidasas/genética , Aminopeptidasas/aislamiento & purificación , Angiotensina II/química , Antagonistas de Receptores de Angiotensina , Animales , Autorradiografía , Encéfalo/citología , Encéfalo/enzimología , Encéfalo/metabolismo , Línea Celular , Cistinil Aminopeptidasa , Hemoglobinas/metabolismo , Humanos , Inmunohistoquímica , Hibridación in Situ , Radioisótopos de Yodo/química , Radioisótopos de Yodo/metabolismo , Ratones , Ratones Endogámicos C57BL , Fragmentos de Péptidos/metabolismo , Ensayo de Unión Radioligante , Receptores de Angiotensina/genética , Receptores de Angiotensina/aislamiento & purificación , Proteínas Recombinantes de Fusión/metabolismo , TransfecciónRESUMEN
The planned revision of the ISO 9000 series of standards means that all medical device companies will have to revise their quality systems to align them with the new ISO 9000:2000 standards. This overview outlines the changes and the factors companies need to consider, and highlights future standards activity.
Asunto(s)
Equipos y Suministros/normas , Industrias/normas , Control de CalidadAsunto(s)
Anestesiología/historia , China , Historia del Siglo XIX , Historia del Siglo XX , HumanosRESUMEN
BACKGROUND: Antibodies to Epstein Barr Virus (EBV) antigens have been used for the diagnosis of nasopharyngeal carcinoma (NPC). While immunofluorescence assays (IFA) of IgA antiviral capsid and early antigens have been the mainstay of this diagnosis, enzyme immunoassays (ELISA) of various EBV antigens are now available. However in almost all of these assays, the sensitivities and specificities have been calculated using blood donors and normal hospital staff as controls, who may not be the most appropriate controls. We wanted to evaluate the usefulness of IFA and ELISA of various EBV antigens in a clinical setting to distinguish between patients with NPC and those suspected of NPC but being biopsy negative. METHODS: Between January 1987 and June 1988, 322 consecutive patients suspected of NPC and who had a post-nasal biopsy were studied. Blood was taken for EBV tests before diagnosis. Tests included IFA and ELISA IgA anti-VCA and anti-EA and ELISA IgA and IgG anti-ribonucleotide reductase, a cloned EA antigen. RESULTS: IFA IgA anti-VCA together with IFA IgA anti-EA both at a cut-off of 1:10 gave the best discrimination between patients with NPC and those suspected of NPC but were biopsy negative. CONCLUSION: The ELISA IgG anti-ribonucleotide reductase test is convenient to perform and looks very promising. An ELISA using a cocktail of cloned EA peptides may be even better.
Asunto(s)
Anticuerpos Antivirales/análisis , Biomarcadores de Tumor/análisis , Carcinoma/diagnóstico , Herpesvirus Humano 4/inmunología , Neoplasias Nasofaríngeas/diagnóstico , Carcinoma/inmunología , Carcinoma/virología , Ensayo de Inmunoadsorción Enzimática/normas , Técnica del Anticuerpo Fluorescente/normas , Humanos , Inmunoglobulina A/análisis , Neoplasias Nasofaríngeas/inmunología , Neoplasias Nasofaríngeas/virología , Estudios Retrospectivos , Sensibilidad y EspecificidadRESUMEN
An open comparative randomised study comparing the performance of hydrocolloid dressings (DuoDERM CGF) to saline gauze dressings in the treatment of pressure ulcers was done to evaluate the overall dressing performance, wound healing and cost effectiveness. Thirty-four subjects were enrolled at the University Hospital, Kuala Lumpur over a 643 days period. Inclusion criteria were Stage II or III pressure ulcers, at least 18 years of age and written informed consent. Only one pressure ulcer per subject was enrolled in the study. Patients with infected pressure ulcers, diabetes mellitus, an immuno-compromised status and known sensitivity to the study dressings were excluded. Subjects who met the enrollment criteria were randomised to one of the two dressing regimes. They were expected to participate in the study for a maximum of eight weeks or until the pressure ulcer healed, which ever occurred first. Overall subject age averaged 58 years and the mean duration of pressure ulcer existence was about 1 month. Twenty-one of the thirty-four ulcers enrolled were stage II and thirteen were stage III. The majority of the ulcers (88%) were located in the sacral area and seventeen subjects (50%) were incontinent. In the evaluation of dressing performance in terms of adherence to wound bed, exudate handling ability, overall comfort and pain during dressing removal; all favoured the hydrocolloid dressing by a statistically significant margin (p < 0.001). Subjects assigned the hydrocolloid dressing experienced a mean 34% reduction from their baseline surface area measurement compared to a mean 9% increase by subjects assigned gauze dressings. This was not statistically significant (p = 0.2318). In cost evaluation of the study products, there was no statistical significance in the total cost of wound management per subject. When only labour time and cost was evaluated, there was a statistically significant advantage towards hydrocolloid dressings.
Asunto(s)
Coloides/uso terapéutico , Apósitos Oclusivos , Úlcera por Presión/terapia , Cloruro de Sodio/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Análisis Costo-Beneficio , Humanos , Persona de Mediana Edad , Apósitos Oclusivos/economía , Apósitos Oclusivos/normas , Úlcera por Presión/fisiopatología , Cicatrización de HeridasRESUMEN
A retrospective study was carried out on 42 patients (38 males, 4 females, mean age 25.9) with liver injury at the University Hospital, Kuala Lumpur from 1994 through to 1991. Prognostic factors that might help to identify those patient survival was related to pulse rate on arrival ( < or = 120 beats per minute, p = 0.027), systolic blood pressure at induction of anaesthesia ( > or = to 80 mmHg, p = 0.003) and intraoperative blood transfusion of < or = to 4 units (p = 0.05). This data were supported by the 95% confidence interval suggesting that these factors may be strong prognostic indicators individually. Increased mortality was also associated with increased total blood transfused (p = 0.002) and grade of liver injury (p = 0.02). Although the factors we have identified reflect both the severity of injury and resuscitative and surgical efforts, further studies using a prospective design are required to confirm these findings.
Asunto(s)
Hígado/lesiones , Adolescente , Adulto , Transfusión Sanguínea , Niño , Preescolar , Femenino , Hospitales Universitarios , Humanos , Malasia , Masculino , Persona de Mediana Edad , Pronóstico , Factores de TiempoRESUMEN
The LHRH receptor in alpha T3-1 gonadotrope cells was shown to bring about a marked and sustained activation of MAP kinase. This response was prevented by protein kinase C inhibition or down-regulation and could be partially mimicked by phorbol ester. Additional evidence for inhibition of this response by pertussis toxin and partial mimicry by mastoparan (in a pertussis toxin-sensitive manner) provides the first evidence for Gi/Go-mediated signal transduction by the LHRH receptor. This dual mechanism of MAP kinase activation appears to be exceptional amongst the G protein-linked receptors that have been investigated.
Asunto(s)
Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Proteínas de Unión al GTP/fisiología , Toxina del Pertussis , Adenohipófisis/enzimología , Proteína Quinasa C/metabolismo , Receptores LHRH/fisiología , Factores de Virulencia de Bordetella/farmacología , Línea Celular , Activación Enzimática/efectos de los fármacos , Hormona Liberadora de Gonadotropina/farmacología , Fosfatos de Inositol/metabolismo , Péptidos y Proteínas de Señalización Intercelular , Cinética , Péptidos , Forbol 12,13-Dibutirato/farmacología , Proteína Quinasa C/antagonistas & inhibidores , Transducción de Señal , Venenos de Avispas/farmacologíaRESUMEN
Malignant fibrous histiocytoma is a mesenchymal tumour which can involve the genitourinary organs primarily or by secondary extension. Both conditions are rare. We report four cases of retroperitoneal malignant fibrous histiocytoma involving the kidney by local extension. Diagnosis was difficult because of diverse, non-specific clinical features and may only be reached at operation or post mortem. Prognosis is poor. Although en bloc tumour resection with nephrectomy was possible in two patients, they returned with recurrences.
Asunto(s)
Histiocitoma Fibroso Benigno/diagnóstico por imagen , Riñón/diagnóstico por imagen , Neoplasias Retroperitoneales/diagnóstico por imagen , Adulto , Anciano , Femenino , Histiocitoma Fibroso Benigno/patología , Histiocitoma Fibroso Benigno/cirugía , Humanos , Riñón/cirugía , Masculino , Recurrencia Local de Neoplasia , Nefrectomía , Neoplasias Retroperitoneales/patología , Neoplasias Retroperitoneales/cirugía , UrografíaAsunto(s)
Proteínas de Unión al GTP/metabolismo , Fosfolipasa D/metabolismo , Proteínas Tirosina Quinasas Receptoras/metabolismo , Fosfolipasas de Tipo C/metabolismo , Animales , Línea Celular , Activación Enzimática , Hormona Liberadora de Gonadotropina/farmacología , Homeostasis , Fosfatos de Inositol/metabolismo , CinéticaAsunto(s)
Hormona Liberadora de Gonadotropina/farmacología , Fosfatos de Inositol/metabolismo , Proteínas Tirosina Quinasas/metabolismo , Receptores LHRH/fisiología , Fosfolipasas de Tipo C/metabolismo , Animales , Línea Celular , Cinamatos/farmacología , Activación Enzimática , Estrógenos/farmacología , Genisteína , Isoflavonas/farmacología , Cinética , Fenoles/farmacología , Hipófisis , Proteínas Tirosina Quinasas/antagonistas & inhibidoresAsunto(s)
Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Hormona Liberadora de Gonadotropina/farmacología , Toxina del Pertussis , Proteína Quinasa C/metabolismo , Receptores LHRH/fisiología , Factores de Virulencia de Bordetella/farmacología , Animales , Línea Celular , Activación Enzimática , Indoles/farmacología , Cinética , Maleimidas/farmacología , Forbol 12,13-Dibutirato/farmacología , Proteína Quinasa C/antagonistas & inhibidores , Receptores LHRH/efectos de los fármacosRESUMEN
A case is reported of retroperitoneal malignant fibrous histiocytoma (MFH) invading into the colon, causing fresh bleeding per rectum. It illustrates the difficulty encountered in the pre-operative diagnosis of this condition, especially in a patient with an atypical presentation of profuse lower gastrointestinal bleeding.